This content is from: Premium
Ventyx’s RX for Going Public
Third Point, Citadel, and other hedge funds are gearing up for this biopharma IPO less than a month after investing in the company’s latest financing round.
Now this is what you call late-stage financing. Ventyx Biosciences Wednesday evening filed initial plans to go public, just 20 days after it closed on its latest private financing round. At least five hedge fund firms have an interest in the company, two of whom hold sizable stakes.It is not unusual for
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.